American Journal of Neuroradiology, Vol 16, Issue 2 373-380, Copyright © 1995 by American Society of Neuroradiology
ARTICLES |
The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis [published erratum appears in AJNR Am J Neuroradiol 1995 Jun-Jul;16(6):1384]
WT Yuh, ET Tali, HD Nguyen, TM Simonson, NA Mayr and DJ Fisher
Department of Radiology, University of Iowa College of Medicine, Iowa City, USA.
PURPOSE: To evaluate the effect of MR contrast dose versus delayed imaging time on the detection of metastatic brain lesions based on lesion size. METHODS: Contrast MR examinations with gadoteridol were obtained in 45 patients with brain metastases. The patients were divided into two groups: 16 received cumulative standard dose (0.1 mmol/kg) and 29 received cumulative triple dose (0.3 mmol/kg). Both groups were evaluated at two dose levels (lower dose and higher dose) with two separate injections. Each patient received an initial bolus injection of either 0.05 (cumulative standard dose) or 0.1 (cumulative triple dose) mmol/kg of gadoteridol to reach the lower-dose level and underwent imaging immediately and 10 and 20 minutes later. Thirty minutes after injection, an additional bolus injection of 0.05 (cumulative standard dose) or 0.2 (cumulative triple dose) mmol/kg was administered to reach the cumulative higher-dose level (cumulative standard dose, 0.1 mmol/kg; cumulative triple dose, 0.3 mmol). Images were acquired immediately. RESULTS: There was no difference in the detection rate for lesions larger than 10 mm among T2-weighted, lower- dose immediate and delayed, or immediate higher-dose images in both study groups. Lesions smaller than 10 mm had improved detection with delayed imaging in both study groups; however, the immediate higher- dose studies still had the highest detection rate. CONCLUSION: In the evaluation of small central nervous system metastases, either delayed imaging after the injection of standard contrast dose or higher contrast dose may improve their detection, and therefore affect clinical management. Higher contrast dose (cumulative triple dose) studies appear to be more effective than delayed imaging with standard dose.
This article has been cited by other articles:
 |
|
 |
|
  Y. Kato, S. Higano, H. Tamura, S. Mugikura, A. Umetsu, T. Murata, and S. Takahashi Usefulness of Contrast-Enhanced T1-Weighted Sampling Perfection with Application-Optimized Contrasts by Using Different Flip Angle Evolutions in Detection of Small Brain Metastasis at 3T MR Imaging: Comparison with Magnetization-Prepared Rapid Acquisition of Gradient Echo Imaging AJNR Am. J. Neuroradiol., May 1, 2009; 30(5): 923 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.J. Wippold II and for the Expert Panel on Neurologic Imaging Focal Neurologic Deficit AJNR Am. J. Neuroradiol., November 1, 2008; 29(10): 1998 - 2000. [Full Text] [PDF]
|
|
|
|
|
|
Y.-F. Qian, C.-L. Yu, C. Zhang, and Y.-Q. Yu MR T1-Weighted Inversion Recovery Imaging in Detecting Brain Metastases: Could It Replace T1-Weighted Spin-Echo Imaging? AJNR Am. J. Neuroradiol., April 1, 2008; 29(4): 701 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.T. Lucato, M.S. Guedes, J.R. Sato, L.A. Bacheschi, L.R. Machado, and C.C. Leite The Role of Conventional MR Imaging Sequences in the Evaluation of Neurocysticercosis: Impact on Characterization of the Scolex and Lesion Burden AJNR Am. J. Neuroradiol., September 1, 2007; 28(8): 1501 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cha, J.M. Lupo, M.-H. Chen, K.R. Lamborn, M.W. McDermott, M.S. Berger, S.J. Nelson, and W.P. Dillon Differentiation of Glioblastoma Multiforme and Single Brain Metastasis by Peak Height and Percentage of Signal Intensity Recovery Derived from Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging AJNR Am. J. Neuroradiol., June 1, 2007; 28(6): 1078 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Maravilla, J. A. Maldjian, I. M. Schmalfuss, M. J. Kuhn, B. C. Bowen, F. J. Wippold II, V. M. Runge, M. V. Knopp, S. Kremer, L. J. Wolansky, et al. Contrast Enhancement of Central Nervous System Lesions: Multicenter Intraindividual Crossover Comparative Study of Two MR Contrast Agents Radiology, August 1, 2006; 240(2): 389 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Krautmacher, W. A. Willinek, H. J. Tschampa, M. Born, F. Traber, J. Gieseke, H. J. Textor, H. H. Schild, and C. K. Kuhl Brain Tumors: Full- and Half-Dose Contrast-enhanced MR Imaging at 3.0 T Compared with 1.5 T--Initial Experience Radiology, December 1, 2005; 237(3): 1014 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Rumboldt, L. Lambert, J. Talan-Hranilovic, D. Marjan, and T. Sajko Nonenhancing Spinal Subdural Metastatic Tumor AJNR Am. J. Neuroradiol., October 1, 2005; 26(9): 2406 - 2409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Knopp, V. M. Runge, M. Essig, M. Hartman, O. Jansen, M. A. Kirchin, A. Moeller, A. H. Seeberg, and K.-P. Lodemann Primary and Secondary Brain Tumors at MR Imaging: Bicentric Intraindividual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine Radiology, January 1, 2004; 230(1): 55 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Essig, M. Waschkies, F. Wenz, J. Debus, H. R. Hentrich, and M. V. Knopp Assessment of Brain Metastases with Dynamic Susceptibility-weighted Contrast-enhanced MR Imaging: Initial Results Radiology, July 1, 2003; 228(1): 193 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. I. Grossman BRAIN IMAGING AJNR Am. J. Neuroradiol., January 1, 2000; 21(1): 9 - 18. [Full Text] [PDF]
|
|